{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:20:05Z","timestamp":1787761205239,"version":"build-2784847793"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL156866"],"award-info":[{"award-number":["HL156866"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bvth.2026.100192","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:11:59Z","timestamp":1783959119000},"page":"100192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sirolimus outperforms alpelisib in models of NRASQ61R-driven vascular overgrowth"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-3849","authenticated-orcid":false,"given":"Svatava","family":"Merkle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4477-9592","authenticated-orcid":false,"given":"Sara","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pastura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-0956","authenticated-orcid":false,"given":"C. Griffin","family":"McDaniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-2703","authenticated-orcid":false,"given":"Timothy D.","family":"Le Cras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bvth.2026.100192_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13023-024-03196-9","article-title":"Assessment of gene\u2013disease associations and recommendations for genetic testing for somatic variants in vascular anomalies by VASCERN-VASCA","volume":"19","author":"Revencu","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"suppl 3","key":"10.1016\/j.bvth.2026.100192_bib2","article-title":"How we approach the diagnosis and management of complex lymphatic anomalies","volume":"69","author":"Ricci","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bvth.2026.100192_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCRESAHA.121.318145","article-title":"Genetic basis and therapies for vascular anomalies","volume":"129","author":"Queisser","year":"2021","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.bvth.2026.100192_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31605","article-title":"RAS pathway mutations and therapeutics in vascular anomalies","volume":"72","author":"Alharbi","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.bvth.2026.100192_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30219","article-title":"Kaposiform lymphangiomatosis: diagnosis, pathogenesis, and treatment","volume":"70","author":"McDaniel","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.bvth.2026.100192_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpeds.2013.10.013","article-title":"Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly","volume":"164","author":"Croteau","year":"2014","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.bvth.2026.100192_bib7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/s41436-018-0390-0","article-title":"A somatic activating NRAS variant associated with kaposiform lymphangiomatosis","volume":"21","author":"Barclay","year":"2019","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.bvth.2026.100192_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10456-022-09836-7","article-title":"NRASQ61R mutation in human endothelial cells causes vascular malformations","volume":"25","author":"Boscolo","year":"2022","journal-title":"Angiogenesis"},{"issue":"17","key":"10.1016\/j.bvth.2026.100192_bib9","doi-asserted-by":"crossref","first-page":"e31032","DOI":"10.1002\/pbc.31032","article-title":"NRASQ61R mutation drives elevated angiopoietin-2 expression in human endothelial cells and a genetic mouse model","volume":"71","author":"Pastura","year":"2024","journal-title":"Pediatric Blood Cancer"},{"issue":"3","key":"10.1016\/j.bvth.2026.100192_bib10","doi-asserted-by":"crossref","first-page":"e70002","DOI":"10.1002\/1545-5017.70002","article-title":"MEK inhibition reduces vascular malformations and gene dysregulation in NRAS Q61R human endothelial cells","volume":"73","author":"Alharbi","year":"2026","journal-title":"Pediatric Blood Cancer"},{"issue":"2","key":"10.1016\/j.bvth.2026.100192_bib11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"PEDIATRICS"},{"issue":"8","key":"10.1016\/j.bvth.2026.100192_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28936","article-title":"Severe adverse events during sirolimus \u201coff-label\u201d therapy for vascular anomalies","volume":"68","author":"R\u00f6ssler","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bvth.2026.100192_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100133","article-title":"Alpelisib, a PI3K\u03b1 inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes","volume":"3","author":"Pithadia","year":"2026","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"9","key":"10.1016\/j.bvth.2026.100192_bib14","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1172\/JCI76004","article-title":"Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects","volume":"125","author":"Boscolo","year":"2015","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.bvth.2026.100192_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3892\/or.2020.7674","article-title":"Selective inhibition of PI3K110\u03b1 as a novel therapeutic strategy for cetuximab-resistant oral squamous cell carcinoma","volume":"44","author":"Tsuchihashi","year":"2020","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.bvth.2026.100192_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/hematology.2024000599","article-title":"Targeted medical therapies for vascular anomalies","volume":"2024","author":"Borst","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.bvth.2026.100192_bib17","series-title":"Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","year":"2005"},{"issue":"5","key":"10.1016\/j.bvth.2026.100192_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4161\/cbt.28164","article-title":"Lifespan extension and cancer prevention in HER-2\/neu transgenic mice treated with low intermittent doses of rapamycin","volume":"15","author":"Popovich","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.bvth.2026.100192_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31492","article-title":"Lyve1-driven NrasQ61R causes edema, enlarged lymphatic vessels, and hepatic vascular defects in embryonic mice","volume":"72","author":"McDaniel","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.bvth.2026.100192_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bvth.2026.100192_bib21","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bvth.2026.100192_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/CIRCRESAHA.119.316500","article-title":"Somatic gain of KRAS function in the endothelium is sufficient to cause vascular malformations that require MEK but not PI3K signaling","volume":"127","author":"Fish","year":"2020","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.bvth.2026.100192_bib23","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.celrep.2018.08.025","article-title":"Activation of Ras in the vascular endothelium induces brain vascular malformations and hemorrhagic stroke","volume":"24","author":"Li","year":"2018","journal-title":"Cell Rep"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:26:51Z","timestamp":1787758011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950327226000574"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100192","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus outperforms alpelisib in models of NRASQ61R-driven vascular overgrowth","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100192"}}